A 52-year-old woman with dilated cardiomyopathy (LVEF 25%) and chronic heart failure presents with recurrent episodes of polymorphic ventricular tachycardia. Her serum potassium is 3.2 mmol/L, magnesium is 1.6 mg/dL, and QTc interval is 480 ms. After correction of electrolytes, which drug is most appropriate for long-term prevention of recurrent arrhythmias?

Explanation

## Clinical Context: Polymorphic VT in Cardiomyopathy **Key Point:** Polymorphic VT in a patient with severely reduced LVEF and underlying structural heart disease (dilated cardiomyopathy) carries high mortality and requires aggressive antiarrhythmic therapy. **High-Yield:** In patients with cardiomyopathy and reduced LVEF, amiodarone is the most effective oral antiarrhythmic for suppressing both monomorphic and polymorphic VT, with the best survival benefit. ## Differential Diagnosis of Polymorphic VT | Feature | Torsades de Pointes | Polymorphic VT (Structural) | |---------|-------------------|------------------------------| | QTc prolongation | Present (>460 ms) | Usually normal | | Cause | Acquired/congenital long QT | Structural heart disease | | Trigger | Bradycardia, pause-dependent | Ischemia, catecholaminergic | | Treatment | Correct QT, avoid QT-prolonging drugs | Amiodarone, beta-blocker, ICD | **Clinical Pearl:** This patient has electrolyte depletion (K^+^ 3.2, Mg^2+^ 1.6) which can prolong QTc and predispose to torsades. However, the underlying diagnosis is polymorphic VT secondary to cardiomyopathy, not primary long QT syndrome. ## Antiarrhythmic Drug Comparison in Cardiomyopathy ```mermaid flowchart TD A[Polymorphic VT + Cardiomyopathy<br/>LVEF 25%]:::outcome --> B{Mechanism & Safety}:::decision B -->|Class IA/IC: Proarrhythmic| C[Flecainide, Procainamide]:::urgent C --> D[Increased mortality in<br/>structural heart disease]:::urgent B -->|Class II: Beta-blocker| E[Metoprolol, Carvedilol]:::action E --> F[Useful but insufficient<br/>monotherapy for VT]:::action B -->|Class III: Amiodarone| G[Broad spectrum<br/>antiarrhythmic]:::action G --> H[Most effective for VT<br/>suppression + survival benefit]:::action B -->|Class IV: Verapamil| I[Contraindicated in<br/>cardiomyopathy]:::urgent I --> J[Negative inotrope,<br/>worsens HF]:::urgent ``` **Key Point:** Class IC antiarrhythmics (flecainide) and some Class IA agents are **contraindicated** in structural heart disease because they increase mortality (CAST trial principle). ## Why Amiodarone? 1. **Broad-spectrum action:** Class I, II, III, and IV properties 2. **Efficacy:** 60–70% suppression of VT in cardiomyopathy 3. **Safety in HF:** Unlike other Class I agents, amiodarone does NOT increase mortality in reduced LVEF 4. **Survival benefit:** GESICA and AMIOVIRT trials showed benefit in cardiomyopathy 5. **Polymorphic VT:** Effective for both monomorphic and polymorphic VT **Mnemonic:** **AMIO** = Antiarrhythmic, Multiclass, In cardiomyopathy, Optimal choice ## Limitations of Alternatives | Drug | Reason NOT suitable | |------|---------------------| | **Sotalol** | Beta-blocker + Class III; prolongs QT; risk of torsades in setting of electrolyte depletion; less effective than amiodarone for VT suppression | | **Flecainide** | Class IC; contraindicated in cardiomyopathy (CAST trial); increases mortality | | **Verapamil** | Negative inotrope; worsens HF and LVEF; contraindicated in cardiomyopathy | ## Complete Management Strategy 1. **Acute:** Electrolyte repletion (K^+^ >4.0 mmol/L, Mg^2+^ >2.0 mg/dL) 2. **Chronic pharmacotherapy:** Amiodarone 200–400 mg daily 3. **Adjunctive:** Beta-blocker (carvedilol, metoprolol) for HF and additional arrhythmia suppression 4. **Definitive:** ICD placement (primary prevention given LVEF 25% and symptomatic VT) 5. **Monitoring:** Baseline and periodic thyroid, liver, pulmonary function (amiodarone toxicity) **Clinical Pearl:** Amiodarone is often used as a bridge to ICD implantation or in patients who refuse/cannot tolerate ICD. Long-term amiodarone use requires monitoring for organ toxicity. [cite:Harrison 21e Ch 297; Braunwald's Heart Disease 12e Ch 36]